EUCTR2012-001169-33-DK进行中（未招募）1 期
Effects of tolvaptan on renal sodium and water handling and circulation during inhibition of the nitric oxide system in healthy subjects - SAFA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men and women (fertile women must use contraceptives)
- •Age 18-40 years
- •BMI between 18.5-30 kg/m2
- •Informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a)Arterial hypertension (ofiice BP over 140 mmHg systolisc and/or 90 mmHg diastolic)
- •b)Clincal signs of heart, lung, liver, kidney, brain, endocrine or neplastic diseases
- •c)Alcoholabuse
- •d)Drugabuse.
- •e)Medical treatment, except anticontraceptives
- •g)Pregnancy or nursing
- •h)Clinical important abnormalities in blood or urine samples or during he alt examination
- •i)Clinical important abnormalities in ECG
- •j)Bloddonation within a month of first treatment period
- •k)Allergies towards Tolvaptan.
- •l)Fertile women must use contraceptives
研究者
相似试验
进行中（未招募）
1 期
The effects of tolvaptan on renal handeling of water and salt, hormones in the blood and the circulation, during blocking of the nitric oxide (NO) system in healthy subjects. A dose-response study.HyponatremiaSIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion)MedDRA version: 14.1Level: LLTClassification code 10021038Term: HyponatremiaSystem Organ Class: 100000004861MedDRA version: 14.1Level: LLTClassification code 10040626Term: SIADHSystem Organ Class: 100000004860EUCTR2013-003800-38-DKDepartment of Medical Research22
已完成
2 期
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)Cardiovascular DiseasesNephropathyNCT01638663Regional Hospital Holstebro20
已完成
不适用
The effect of tolvaptan on renal function during intensive treatment in patients with congestive heart failurecongestive heart failureJPRN-UMIN000014134ishiarai Heart Center Hospital80
已完成
2 期
Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)NephropathyNCT02078973Regional Hospital Holstebro15
已完成
2 期
Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemAutosomal Dominant Polycystic Kidney DiseaseNCT02527863Regional Hospital Holstebro18